EUCTR2014-001714-26-Outside-EU/EEA进行中（未招募）不适用
Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru
Sanofi Pasteur SA0 个研究点目标入组 792 人开始时间: 2014年5月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 792
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Aged 12 to 13 months on the day of inclusion.
- •2) Born at full term of pregnancy (=37 weeks) and with a birth weight =2.5 kg as reported by the parent/legally acceptable representative.
- •3) Subject in good health, based on medical history and physical examination.
- •4) Subject has completed his/her vaccination schedule according to the official immunization calendar of Colombia and/or Peru, respectively.
- •5) Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by 2 independent witnesses if required by local regulations).
- •6) Subject and parent/legally acceptable representative/tutor able to attend all scheduled visits and to comply with all trial procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 792
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.
- •2) Planned participation in another clinical trial during the present trial period.
- •3) Planned receipt of any vaccine in the 4 weeks following first trial vaccination.
- •4) Previous vaccination against YF, hepatitis A or measles, mumps and rubella.
- •5) Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response.
- •6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 weeks or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •7) Personal known seropositivity for human immunodeficiency virus (HIV) as reported by the parent/legally acceptable representative.
- •8) History of previous maternal vaccination against YF as reported by the parent/legally acceptable representative.
- •9) Personal history of YF or dengue infection/disease as reported by the
- •parent/legally acceptable representative.
- •10) Known systemic hypersensitivity to any of the vaccine components of the vaccines that will be used in the trial, or history of a life-threatening reaction to the vaccines used in the trial or to vaccines containing any of the same substances.
- •11) History of contraindication to receipt of vaccines containing components of Stamaril (yellow fever vaccine), measles, mumps and rubella vaccine, hepatitis A vaccine, pneumococcal conjugated vaccine or of diphtheria (D) toxoid, tetanus (T) toxoid, pertussis toxoid (PT), filamentous hemagglutinin (FHA), polyribosylribitol phosphate (PRP) and polio or other DTP vaccine (e.g., DTwP).
- •12) Thrombocytopenia, as reported by the parent/legally acceptable representative.
- •13) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
- •14) History of central nervous system disorder or disease, including seizures.
- •15) Personal history of thymic pathology (e.g., thymoma), and/or thymectomy.
- •16) Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
- •17) Identified as a child (adopted or natural) of the Investigator or of employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.
- •Temporary Contraindications:
- •A prospective subject must not be included in the study until the following conditions and/or symptoms are resolved:
- •18) Febrile illness (temperature =38.0°C) or moderate or severe acute
- •illness/infection (according to Investigator judgment) on the day of vaccination.
- •19) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
研究者
相似试验
未知
不适用
IMMUNOGENICITY AND SAFETY OF YELLOW FEVER VACCINE (STAMARIL®) ADMINISTERED CONCOMITANTLY WITH TETRAVALENT DENGUE VACCINE IN HEALTHY TODDLERS AT 12-13 MONTHS OF AGE IN COLOMBIA AND PERPER-037-11SANOFI PASTEUR INC.,320
招募中
不适用
Effectiveness and safety of yellow fever vaccination in patients with rheumatic diseasesC20.111VaccinationYellow Fever VaccineYellow Fever VirusAutoimmune Disease.E02.095.465.425.400.530.890D20.215.894.899.970B04.820.250.350.990RBR-3875ddHospital Universitário Cassiano Antônio de Moraes
尚未招募
不适用
Immunity induced by yellow fever vaccination in the elderly (60yrs or older)travellergele koorts, oudere, reizen, neutraliserende antistoffen, bijwerkingenyellow fever, elderly, travel, neutralizing antibodies, adverse eventsNL-OMON20831A.H.E. Roukens en L.G. Visser60
进行中（未招募）
不适用
Immunity of the Vaccine against Yellow Fever in patients taking medications that affect the immune systemnspecified rheumatoid arthritisM06.9RBR-946bv5Centro de Pesquisas René Rachou- FIOCRUZ
已完成
不适用
ong-term immunity after Yellow fever vaccinatioYellow feverJPRN-UMIN000040526Tokyo Medical University Hospital Travellers' Medical Center50